# US 9,434,978 B2 · Culture medium for screening or enrichment of methicillin-resistant S. aureus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,978 B2
- Document ID: US9434978B2
- Status: Granted
- Kind: B2
- Application number: 13/519,161
- Filed: 2010-12-29
- Published: 2012-12-20
- Granted: 2016-09-06
- Earliest claimed: 2009-12-31
- Assignees: Bio-Rad Innovations
- Applicants: Christine Favier; Agnès Kammoun
- Inventors: Christine Favier; Agnès Kammoun
- Web page: https://patentgrep.com/patent/US9434978B2

## CPC

- C12Q 1/14: Streptococcus; Staphylococcus
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to culture medium for screening or enrichment of methicillin-resistant Staphylococcus aureus (MRSA), which medium comprises a combination of at least two cephalosporins.

## Claims

### Claim 1

A culture medium for screening or enrichment of methicillin-resistant Staphylococcus aureus (MRSA) comprising a combination of cephalosporins selected from the group consisting of cefotetan (CTT) and ceftriaxone (CRO); cefotetan (CTT) and cefpodoxime (CPD); cefsulodin (CFS) and ceftriaxone (CRO); cefsulodin (CFS) and cefepime (FEP); and cefotetan (CTT) and ceftiofur (XLN) and wherein each cephalosporin is present in a concentration of between 1.0 mg/l and 3.5 mg/l.

### Claim 2 (depends on 1)

The culture medium according to claim 1, said medium further comprising a chromogenic agent.

### Claim 3 (depends on 2)

The culture medium according to claim 2, wherein the chromogenic agent is 6 chloro 3-indoxyl phosphate.

### Claim 4 (depends on 1)

The culture medium according to claim 1, wherein said culture medium is an agar culture medium.

### Claim 5 (depends on 1)

The culture medium according to claim 1, wherein said culture medium is a broth.

### Claim 6 (depends on 1)

The culture medium according to claim 1, said culture medium comprising:
a) 1.1 to 2.5 mg/l of cefotetan and 1.5 to 2.5 mg/l of ceftriaxone;
b) 1.75 mg/l cefotetan and 2.4 mg/l ceftriaxone; or
c) 2.4 mg/l cefotetan and 2.4 mg/l ceftriaxone.

### Claim 7 (depends on 1)

The culture medium according to claim 1, said culture medium comprising:
2 mg/l cefotetan and 2 mg/l ceftriaxone,
2.4 mg/l cefotetan and 2.4 mg/l ceftriaxone,
2 mg/l cefotetan and 1.5 mg/l cefpodoxime,
2.5 mg/l cefotetan and 1.8 mg/l cefpodoxime,
3.5 mg/l cefsulodin and 2 mg/l ceftriaxone, or
3 mg/l cefsulodin and 2 mg/l cefepime.

### Claim 8 (depends on 1)

The culture medium according to claim 1, said culture medium further comprising cefoperazone.

### Claim 9 (depends on 8)

The culture medium according to claim 8, wherein said culture medium comprising cefoperazone is at a concentration of between 0.1 mg/l to 3 mg/l.

### Claim 10 (depends on 1)

The culture medium of claim 1, wherein said combination of cephalosporins is cefotetan (CTT) and ceftriaxone (CRO).

### Claim 11 (depends on 1)

The culture medium of claim 1, wherein said combination of cephalosporins is cefotetan (CTT) and cefpodoxime (CPD).

### Claim 12 (depends on 1)

The culture medium of claim 1, wherein said combination of cephalosporins is cefsulodin (CFS) and ceftriaxone (CRO).

### Claim 13 (depends on 1)

The culture medium of claim 1, wherein said combination of cephalosporins is cefsulodin (CFS) and cefepime (FEP).

### Claim 14 (depends on 1)

The culture medium of claim 1, wherein said combination of cephalosporins is cefotetan (CTT) and ceftiofur (XLN).

### Claim 15 (depends on 1)

The culture medium of claim 1, wherein each cephalosporin is present in a concentration of between 1.25 mg/l and 3.5 mg/l.

### Claim 16 (depends on 1)

The culture medium of claim 1, wherein each cephalosporin is present in a concentration of between 1.1 mg/l and 3.5 mg/l.

### Claim 17 (depends on 1)

A method for screening or enriching methicillin-resistant Staphylococcus aureus (MRSA) in a culture medium, which method comprises (i) inoculating the culture medium according to claim 1, with bacteria to test, and (ii) culturing said bacteria in said culture medium.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the bacteria to test are in the form of a clinical sample.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said clinical sample is a nasal swab, a wound sample or a blood sample.

### Claim 20 (depends on 2)

A method for screening or enriching methicillin-resistant Staphylococcus aureus (MRSA) in a culture medium, which method comprises (i) inoculating the culture medium according to claim 2, with bacteria to test, (ii) culturing said bacteria on said culture medium, and (iii) identifying the presence of MRSA strains on said culture medium.